News headlines about Agios Pharmaceuticals (NASDAQ:AGIO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.6900185061547 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s analysis:
- Christopher Bowden Sells 1,700 Shares of Agios Pharmaceuticals Inc (AGIO) Stock (americanbankingnews.com)
- Are Traders Shorting Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares? (vassarnews.com)
- Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) Has Reported Sales Growth of 0.31496 Year Over Year (vassarnews.com)
- Can Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) Return What Investors Are Looking For? ROE Hits -0.394819 (zeelandpress.com)
- $15.93 Million in Sales Expected for Agios Pharmaceuticals Inc (AGIO) This Quarter (americanbankingnews.com)
Agios Pharmaceuticals stock traded up $1.02 during mid-day trading on Friday, reaching $80.72. 170,700 shares of the company traded hands, compared to its average volume of 454,224. Agios Pharmaceuticals has a fifty-two week low of $51.62 and a fifty-two week high of $99.82. The firm has a market capitalization of $4.55 billion, a price-to-earnings ratio of -11.96 and a beta of 1.97.
Several equities analysts recently commented on the stock. BidaskClub downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Piper Jaffray Companies reissued a “buy” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 4th. Cann reissued a “hold” rating on shares of Agios Pharmaceuticals in a research report on Friday, July 20th. SunTrust Banks reissued a “buy” rating and issued a $123.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, July 23rd. Finally, Citigroup started coverage on shares of Agios Pharmaceuticals in a research report on Wednesday, May 23rd. They issued a “buy” rating and a $117.00 price target for the company. Four analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $97.90.
In related news, Director Kaye I. Foster-Cheek sold 9,000 shares of the stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $93.55, for a total transaction of $841,950.00. Following the sale, the director now directly owns 11,200 shares of the company’s stock, valued at $1,047,760. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Biller sold 3,000 shares of the stock in a transaction on Tuesday, June 5th. The stock was sold at an average price of $93.37, for a total transaction of $280,110.00. Following the sale, the insider now directly owns 60,196 shares in the company, valued at $5,620,500.52. The disclosure for this sale can be found here. Insiders sold 28,122 shares of company stock worth $2,484,839 in the last quarter. Company insiders own 3.02% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.